Search Bar & Filters
Found 38 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the clinical effectiveness and safety of a drug called arumakimig MAS825 compared to a placebo in adults with VEXAS syndrome, a rare autoinflammatory condition linked to a mutation in the UBA1 gene. This study is a Phase 2, randomized, double-blind trial focused on participants who are also receiving glucocorticoids. The goal is to assess key disease improvements and the ability to reduce oral glucocorticoid use over 52 weeks. Participants will be randomly assigned to receive either arumakimig or placebo injections for 52 weeks while continuing glucocorticoid therapy, with the option to taper glucocorticoids after the first two weeks based on disease status. After this double-blind phase, eligible participants may enter a 2-year open-label extension to receive arumakimig until Week 156. Following the treatment periods, a 16-week safety follow-up is conducted to monitor long-term safety and tolerability. During the trial, participants will undergo assessments to measure improvements in VEXAS manifestations, glucocorticoid reduction, overall clinical response, flare-free days, and hematologic improvements. Safety will be closely monitored through adverse event tracking up to Week 172. Participants will also complete questionnaires about their disease status. The total participation duration can extend up to approximately three years including treatment, extension, and follow-up periods.
Actively Recruiting
Healthy Volunteer
Researchers are studying the safety, tolerability, and how LY3962681 behaves in the body pharmacokineticspharmacodynamics in healthy volunteers and patients with Parkinsons disease. The trial has two parts a Single Ascending Dose SAD study with healthy volunteers and a Multiple Ascending Dose MAD study with Parkinsons patients. This study is a Phase 1, randomized, double-blind, placebo-controlled trial sponsored by Prevail Therapeutics. In the SAD part, healthy volunteers receive a single intrathecal into spinal fluid dose of LY3962681 or placebo artificial cerebrospinal fluid. In the MAD part, Parkinsons patients receive two intrathecal doses of LY3962681 or placebo spaced 12 to 24 weeks apart. The SAD treatment period lasts one day, while the MAD treatment includes two dosing days spaced several months apart. Participants will undergo safety and tolerability assessments over follow-up periods up to 52 weeks after dosing. Evaluations include monitoring for serious and treatment-emergent adverse events, measuring drug levels in the body, and assessing changes in cerebrospinal fluid biomarkers related to Parkinsons disease. The total study duration may extend for up to 76 weeks, including treatment and follow-up phases.
Actively Recruiting
Researchers are studying MK-7262, a trial medicine designed to lower Lipoproteina Lpa levels in the blood. The study aims to learn about the effects of MK-7262 alone and in combination with another trial medicine called enlicitide, which belongs to a group of medicines that lower low-density lipoprotein cholesterol LDL-C. This Phase 2 clinical trial evaluates the ability of these medicines to reduce Lpa and LDL-C levels and assesses their safety and tolerability. Participants will be randomly assigned to one of four groups MK-7262 with enlicitide, MK-7262 alone, enlicitide alone, or placebo for both medicines. All treatments are given orally once daily for up to approximately 12 weeks. The study is double-blind with placebo controls, and the medicines are taken as coated tablets. The trial monitors effects at specific time points including weeks 8 and 12. During the trial, participants will undergo blood tests to measure changes in Lpa and LDL-C levels from baseline. Researchers will track adverse events and monitor safety for up to about 20 weeks. The primary outcomes include percent changes in Lpa and LDL-C at week 8 and the number of participants experiencing side effects or discontinuing treatment due to side effects. Participation lasts for the treatment period and follow-up assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.
Actively Recruiting
Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating clazakizumab, a drug administered by subcutaneous injection, to study its effect on reducing high-sensitivity C-reactive protein hsCRP, a marker of inflammation, in adults with elevated hsCRP and increased risk for cardiovascular events. This phase 2b, randomized, double-blind, placebo-controlled study focuses on adults with established atherosclerotic cardiovascular disease or other risk factors such as obesity, type 2 diabetes, hypertension, or chronic kidney disease. The study aims to understand how clazakizumab compares to placebo in lowering inflammation related to cardiovascular risk. Participants will receive one of several doses of clazakizumab or a placebo via subcutaneous injection. The treatment period involves dosing and monitoring up to 32 weeks, with the primary outcome measured at 12 weeks and additional assessments at 24 weeks. The study includes a double-blind design where neither participants nor researchers know who receives the active drug or placebo. Pharmacokinetics of clazakizumab will also be evaluated during the trial. Throughout the approximately 9-month participation, participants will undergo blood tests to measure hsCRP levels at baseline and multiple follow-up points, including week 12 and week 24. Researchers will assess the percent change in hsCRP to evaluate inflammation changes. Safety and drug concentration will be monitored regularly. Participants will have scheduled visits for study drug administration and assessments, ensuring careful observation during the study period.
Actively Recruiting
This research aims to evaluate whether participants who have previously taken donanemab experience clinical benefits when receiving annual doses. The study focuses on individuals with Alzheimer disease, dementia, and amyloid plaque conditions, investigating the effects of continued treatment over a period of up to 2.5 years with six visits. The trial is sponsored by Eli Lilly and Company and is conducted as a randomized, double-blind, phase 3 clinical trial. Participants are assigned to receive either donanemab or a placebo, both administered intravenously. The study follows a parallel design where each participant receives one of the two treatments. The annual dosing schedule spans up to 2.5 years, with visits planned throughout this period to monitor participants. This includes assessments of cognitive function, brain amyloid plaque levels via PET scans, plasma biomarkers, and drug concentration measurements. During the study, participants will undergo evaluations including the Clinical Dementia Rating - Sum of Boxes CDR-SB, Cognitive Function Index CFI, Florbetapir F 18 PET scans, and plasma phosphorylated tau measurements. Pharmacokinetics of donanemab will be assessed at baseline, week 52, and week 104. The study involves six visits over the entire duration, with safety and clinical benefit monitored carefully. Participation lasts up to 2.5 years, allowing comprehensive observation of treatment effects.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety, tolerability, and behavior of LY4006896 when given intravenously to healthy adults and people with Parkinsons disease. This study compares LY4006896 with a placebo to understand how the drug interacts with the body and its effects over time. The study includes both healthy volunteers and participants diagnosed with Parkinsons disease, aiming to collect important safety and pharmacokinetic data. Participants with Parkinsons disease will undergo up to four doses of LY4006896 or placebo during a screening period lasting up to 120 days, followed by treatment and follow-up lasting up to 61 weeks. Healthy participants will receive a single escalating dose or placebo in a screening period lasting up to 35 days and be followed for up to 48 weeks. The study involves random assignment to receive either LY4006896 or placebo, with single blinding to ensure unbiased results. Throughout the study, participants will have regular assessments including monitoring for serious or treatment-emergent adverse events, blood sampling for drug concentration measurement, and evaluations of Parkinsons disease-related markers such as alpha-synuclein in skin and cerebrospinal fluid. Participants will be followed for up to 78 weeks Parkinsons group or 53 weeks healthy group to evaluate safety and drug effects. The trial includes detailed cognitive assessments and eligibility screening to ensure participant safety and data reliability.
1-10 of 38
1